SCHEMBL3006743

SCHEMBL3006743

Cc1ccc(F)cc1S(=O)(=O)C1CCN(c2nc(Cc3c(C)cccc3C)cs2)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 5/20 0.37
CTSS P25774 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
MAPK1 P28482 1/20 0.35
ALDH1A1 P00352 2/20 0.34
MAPT P10636 3/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
KMT2A Q03164 1/20 0.34
USP2 O75604 1/20 0.34
RECQL P46063 1/20 0.34
HSD17B10 Q99714 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
DCTPP1 Q9H773 1/20 0.34
POLB P06746 1/20 0.33
USP30 Q70CQ3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3005705 0.93 SMN1; SMN2 (0.36) NAAACTSSSMN1; SMN2MAPK1KMT2A
SCHEMBL3006174 0.92 GPR6 (0.39) NAAACTSSSMN1; SMN2MAPK1ALDH1A1
SCHEMBL3012400 0.90 CTSS (0.48) NAAACTSSSMN1; SMN2MAPK1ALDH1A1
SCHEMBL3013137 0.90 NAAA (0.36) NAAACTSSSMN1; SMN2MAPK1ALDH1A1
SCHEMBL3016669 0.90 NAAA (0.39) NAAACTSSSMN1; SMN2MAPK1ALDH1A1
SCHEMBL3016809 0.89 NAAA (0.40) NAAACTSSSMN1; SMN2MAPK1MEN1
SCHEMBL3014247 0.88 NAAA (0.36) NAAACTSSSMN1; SMN2MAPK1ALDH1A1
SCHEMBL3023017 0.88 ALDH1A1 (0.43) SMN1; SMN2ALDH1A1MAPTLMNAUSP2
SCHEMBL3015041 0.88 NAAA (0.36) NAAACTSSSMN1; SMN2MAPK1MAPT
SCHEMBL3007172 0.88 MAPT (0.41) SMN1; SMN2MAPK1ALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA NAAA 3229/4885CTSS 106/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.